Comparison of Analgesic Efficacy Between Intrathecal Morphine and Intrathecal Nalbuphine After Total Knee Arthroplasty at Makarak Hospital, Kanchanaburi Province

Authors

  • Temsiri Srabua M.D., Makarak Hospital

Keywords:

analgesic efficacy, intrathecal morphine, intrathecal nalbuphine, total knee arthroplasty

Abstract

Objective: This study aimed to compare the analgesic efficacy and dosages of anti-adverse drugs between intrathecal morphine and intrathecal nalbuphine in patients undergoing total knee arthroplasty.

Methods: This was a retrospective cohort analytical review collecting data from the medical records of 52 cases between 1 August 2022 and 31 July 2023, which were divided into 26 cases receiving 0.1 mg intrathecal morphine and 26 cases receiving 1.2 mg intrathecal nalbuphine. Subsequently, the analgesic efficacy and dosages of the anti-adverse drugs were compared. Data were analyzed using descriptive statistics (number, percentage, mean, and standard deviation) and inferential statistics (chi-square or Fisher’s exact test and the independent t test).

Results: The demographic data were not statistically different between the two groups. The group receiving intrathecal morphine had significantly longer duration of effective analgesia than the group receiving intrathecal nalbuphine (1110.30 ± 647.31 minutes vs. 523.57 ± 593.64 minutes; p = .001). The group receiving intrathecal nalbuphine showed less total cumulative morphine doses after surgery than the group receiving intrathecal morphine with a statistically significant difference at 36 hours (1.15 ± 2.09 mg vs. 2.65 ± 2.44 mg; p = .021) and at 48 hours (0.11 ± 0.58 mg vs. 0.69 ± 1.28 mg; p = .045). There were not significantly statistic differences regarding the doses of other analgesic, antiemetic, and antipruritic drugs.

Conclusion: Intrathecal morphine still provides good postoperative pain relief after total knee arthroplasty because the duration of effective analgesia after surgery was longer than the group receiving intrathecal nalbuphine with combined multimodal analgesia.

 

References

กีรติ เจริญชลวานิช. บทนำสู่การผ่าตัดเปลี่ยนข้อเข่าเทียม. ใน: กีรติ เจริญชลวานิช, บรรณาธิการ. ศัลยศาสตร์บูรณภาพข้อเข่าเสื่อม. กรุงเทพมหานคร: ศิริราช; 2559. 118–25.

ปิยะ ปิ่นศรศักดิ์. โรคข้อเข่าเสื่อม พยาธิกำเนิด การวินิจฉัย และการรักษา. ใน: ปิยะ ปิ่นศรศักดิ์, บรรณาธิการ. ภาวะแทรกซ้อนภายหลังการผ่าตัดเปลี่ยนข้อเข่าเทียม การรักษาและการป้องกัน. กรุงเทพมหานคร: กรุงเทพเวชสาร; 2562. 2–55.

Lavand' homme PM, Kehlet H, Rawal N, et al. Pain management after total knee arthroplasty: PROcedure SPEcific postoperative pain management recommendations. Eur J Anaesthesiol 2022;39(9):743–57. doi: 10.1097/EJA.0000000000001691.

กีรติ เจริญชลวานิช. การดูแลผู้ป่วยระหว่างและหลังผ่าตัดเปลี่ยนข้อเข่าเทียม. ใน: กีรติ เจริญชลวานิช, บรรณาธิการ. ศัลยศาสตร์บูรณภาพข้อเข่าเสื่อม. กรุงเทพมหานคร: ศิริราช; 2559. 246–57.

มาร์วิน เทพโสพรรณ, อินทิรา เรืองกรี. การทบทวนบทความของยานาลบูฟีน. วิสัญญีสาร 2565;48(1):59–66.

Patil V, Kondikar L, Balaraju TC, et al. A comparative study of the analgesic efficacy of intrathecal nalbuphine in three different doses (1.0 mg/ 1.5 mg/ 2.0 mg) as an adjuvant to 0.5% hyperbaric bupivacaine in spinal anaesthesia for lower abdominal and lower limb surgeries. MedPulse Int J Anesthesiol 2019;11(1):30–4. doi: 10.26611/10151116

Sharma A, Chaudhary S, Kumar M, et al. Comparison of nalbuphine versus fentanyl as intrathecal adjuvant to bupivacaine for orthopedic surgeries: A randomized controlled double-blind trial. J Anaesthesiol Clin Pharmacol 2021;37(4):529–36. doi: 10.4103/joacp.JOACP_270_18.

Thote RJ, Lomate P, Gaikwad S, et al. Comparison among intrathecal fentanyl and nalbuphine in combination with bupivacaine and plain bupivacaine for lower limb surgeries. Int J Recent Trends Sci Tech 2015;14(2):361–6.

Shah MS, Masoodi T, Hussain SY, et al. Nalbuphine as an intrathecal adjuvant to 0.5% hyperbaric bupivacaine in two different doses for postoperative analgesia after abdominal hysterectomy: a prospective, randomized, double-blind control study. Cureus 2022;14(5):e25044. doi: 10.7759/cureus.25044.

Yu P, Zhang J, Wang J. Nalbuphine for spinal anesthesia: a systematic review and meta-analysis. Pain Pract 2022;22(1):91–106. doi: 10.1111/papr.13021.

Ahmed FI. Intrathecal nalbuphine versus fentanyl as an adjuvant to bupivacaine in spinal anesthesia for elective cesarean section: a randomized double-blind study. Res Opin Anesth Intensive Care 2019;6(1):112–8. doi: 10.4103/roaic.roaic_109_17

Garg K, Garg P, Katyal S. Comparative analysis of intrathecal nalbuphine vs fentanyl as an adjuvant to bupivacaine for urological procedures. MGM J Med Sci 2020;7(4):203–8. doi: 10.4103/mgmj.mgmj_67_20

Published

2025-06-30

How to Cite

1.
Srabua T. Comparison of Analgesic Efficacy Between Intrathecal Morphine and Intrathecal Nalbuphine After Total Knee Arthroplasty at Makarak Hospital, Kanchanaburi Province. Reg 4-5 Med J [internet]. 2025 Jun. 30 [cited 2026 Feb. 22];44(2):259-72. available from: https://he02.tci-thaijo.org/index.php/reg45/article/view/276480